Clinical trial
A Phase 3, Randomized, Double-blind Trial of Nivolumab in Combination With Intravesical BCG Versus Standard of Care BCG Alone in Participants With High-risk Non-muscle Invasive Bladder Cancer That Is Persistent or Recurrent After Treatment With BCG
NCT04149574 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Randomized, Double-blind Trial of Nivolumab in Combination With Intravesical BCG Versus Standard of Care BCG Alone in Participants With High-risk Non-muscle Invasive Bladder Cancer That Is Persistent or Recurrent After Treatment With BCG
- Lead sponsor
- Bristol-Myers Squibb
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- January 15, 2020
- Completion date
- October 31, 2023
- Enrollment
- 13 (actual)
- Sites
- 63
Conditions
As the registry lists them; a condition with its own page is linked.